Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Rating of "Buy" by Analysts

Key Points

• Voyager Therapeutics has received a consensus rating of "Buy" from eight analysts, with seven ratings being "buy" and one "strong buy." The average price target set by analysts is $13.25.
• The company's recent quarterly earnings report showed a loss of ($0.57) EPS, missing expectations, with revenues of $5.20 million, below analyst estimates of $9.50 million.
• Institutional investors currently hold 48.03% of Voyager Therapeutics' stock, indicating significant interest from larger investment entities.

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have received a consensus recommendation of "Buy" from the eight ratings firms that are currently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $13.2471.

VYGR has been the topic of a number of recent research reports. Wedbush decreased their target price on Voyager Therapeutics from $9.00 to $8.00 and set an "outperform" rating on the stock in a report on Thursday, August 7th. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price target on shares of Voyager Therapeutics in a report on Monday, September 15th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC lifted its stake in shares of Voyager Therapeutics by 179.3% in the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company's stock worth $1,674,000 after acquiring an additional 317,927 shares during the period. Acadian Asset Management LLC lifted its position in shares of Voyager Therapeutics by 863.3% during the first quarter. Acadian Asset Management LLC now owns 230,708 shares of the company's stock worth $778,000 after purchasing an additional 206,758 shares in the last quarter. Nuveen LLC acquired a new stake in Voyager Therapeutics in the first quarter valued at $368,000. Hsbc Holdings PLC grew its position in shares of Voyager Therapeutics by 118.5% during the second quarter. Hsbc Holdings PLC now owns 148,377 shares of the company's stock worth $440,000 after acquiring an additional 80,474 shares during the last quarter. Finally, Strs Ohio bought a new position in Voyager Therapeutics in the 1st quarter valued at about $256,000. 48.03% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Stock Down 4.9%

Shares of VYGR traded down $0.22 during midday trading on Thursday, hitting $4.27. The company's stock had a trading volume of 915,232 shares, compared to its average volume of 688,171. The stock has a market capitalization of $236.85 million, a price-to-earnings ratio of -2.31 and a beta of 0.90. Voyager Therapeutics has a one year low of $2.64 and a one year high of $8.27. The company's fifty day simple moving average is $3.56 and its two-hundred day simple moving average is $3.42.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.09). The firm had revenue of $5.20 million for the quarter, compared to the consensus estimate of $9.50 million. Voyager Therapeutics had a negative net margin of 253.49% and a negative return on equity of 37.65%. On average, research analysts predict that Voyager Therapeutics will post -0.91 earnings per share for the current year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.